A Phase One, Open Label, Two-Period, Two-Treatment, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of PF-06463922 In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Lorlatinib (Primary) ; Rifampicin
- Indications Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 10 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.